David Nathaniel E 4
4 · Unity Biotechnology, Inc. · Filed Sep 23, 2019
Insider Transaction Report
Form 4
David Nathaniel E
DirectorPresident
Transactions
- Award
Stock Option (Right to Buy)
2019-09-19+27,825→ 27,825 totalExercise: $3.43From: 2019-09-19Exp: 2027-09-25→ Common Stock (27,825 underlying)
Holdings
- 2,299,731
Common Stock, $0.0001 par value
Footnotes (2)
- [F1]Includes Restricted Stock Units which vest over time measured from the grant date.
- [F2]On September 26, 2017, Reporting Person was granted an option exercisable for 138,417 shares. 27,118 shares vested as of December 31, 2018. Of the remaining shares, twenty-five percent (25%) was subject to vesting pursuant to the achievement of a clinical development milestone; in this case proof of concept that treatment with a senolytic drug meaningfully ameliorates a human disease. On September 19, 2019, Issuer's Board of Directors determined that such milestone was achieved.